Intravenous Recombinant Tissue-Type Plasminogen Activator (Rt-Pa) for the Treatment of Acute Ischemic Stroke: More Risks than Benefits?

german translation / full article

Two articles in the British Medical Journal discuss the pros and cons of intravenous recombinant tissue-type plasminogen activator (rt-PA) for the treatment of acute ischemic stroke. Simon Brown and Stephen Macdonald argue that patients with stroke should not be given thrombolysis outside clinical trials, but Graeme Hankey says the benefits are clear in carefully selected patients.

(State: 13.05.2015)

Latest Issue 9/2020

In Focus

  • Clinical Characteristics of SARS-CoV-2 Tested Patients
  • Urinary Incontinence in Family Practice
  • Challenges in Southern Bavarian Primary Care Practices During the COVID-19 Pandemic